Cyclerion Therapeutics Announces Departure of Chief Medical Officer
March 18, 2021 17:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
February 25, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers...
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
January 25, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 ...
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
January 04, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious...
Cyclerion Announces Leadership Transitions
December 21, 2020 07:30 ET
|
Cyclerion Therapeutics, Inc.
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating Officer Amy Schulman stepping down from Board of Directors ...
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
November 05, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant improvements in multiple measures associated with age-related cognitive decline and neurodegenerative...
Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects
October 14, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
Showed significant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases Confirmed blood-brain-barrier...
Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease
October 14, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company, today announced top-line results from its STRONG-SCD...
Cyclerion to Participate at Upcoming September 2020 Investor Conferences
September 04, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
August 25, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases,...